Zeta CD27 Antibody. Zeta’s recombinant rabbit antibody recognizes CD27, a transmembrane phosphoglycoprotein that belongs to the tumor necrosis factor receptor (TNFR) superfamily which is also known as tumor necrosis factor receptor superfamily member 7 (TNFRSF7). CD27 is a protein of a disulfide-linked 120kDa dimer that is triggered by its unique ligand D CD70, which is expressed on immune cells and often in cancers. CD27 is expressed on the majority of peripheral T cells, medullary thymocytes, memory-type B cells, and natural killer cells. CD27 binds to its ligand CD70, a member of the TNF family, and induces T-cell co-stimulation and B-cell activation. CD27 also interacts with TRAFs and is involved in activation of NFkappa B and SAPK/JNK and induces apoptosis.
When identified in patient tumors, CD27 can help in solid tumors to predict poorer survival when CD27 positive tumor infiltrating lymphocytes are present in renal cell carcinoma, improved survival for negative tumor infiltrating lymphocytes in high grade serous ovarian carcinoma or hepatocellular carcinomas. CD27 can also help with hematolymphoid neoplasms where soluble CD27 is an unfavorable prognostic marker in acute myeloid leukemia, and CD27 is highly expressed and indicated decreased survival in high-risk B cell progenitor acute lymphoblastic leukemia.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.